Prostate Cancer: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 67-year-old man with a history of hypertension and hyperlipidemia presents to your oncology clinic after a new diagnosis of metastatic prostate cancer. He has bone metastases in the pelvis, his left femur, and T12, and a PSA of 137. Despite this he is relatively asymptomatic with only mild back pain and slight fatigue.  After reviewing his case, you start him on androgen deprivation therapy (ADT) and abiraterone acetate per standard management for metastatic hormone sensitive prostate cancer. In your discussion with him and his wife, you learn that his sister was diagnosed with breast cancer at 42, and his mother had ovarian cancer at 48. He has three children (son and two daughters), and he and his wife are wondering about whether he should undergo genetic testing as part of his clinical work up.

Learning Objectives:
1. Identify the significance of germline BRCA2 mutations in the development of prostate cancer and other malignancies in men and their family
2. Describe the extent of mutations in DNA-repair genes in metastatic prostate cancers and explain the principles behind PARP inhibition as a form of targeted therapy
3. Enumerate the DNA-repair genes in advanced prostate cancer to likely influence management decisions

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on August 22, 2020. Participants must complete all necessary course components by this date to receive credit